PHILADELPHIA, Aug. 10 /PRNewswire-FirstCall/ -- ERT (Nasdaq: ERES), a leading provider of centralized services to globalpharmaceutical, biotechnology and medical device companies, announces that Joel Morganroth, MD, Chairman and Chief Scientist, has been acknowledged by PharmaVOICE magazine as one of the 100 most inspiring people
"I am especially honored to have been nominated to receive this prestigious award," Dr. Morganroth stated. "This recognition would not have been possible had I not been part of such an innovative company and competent team of experts, committed to redefining how clinical trials can be successfully conducted to allow for quick and accurate product development decisions."
Dr. Morganroth was nominated for the PharmaVOICE 100 award based on his outstanding career in the life sciences industry spanning more than 30 years and his ability to inspire and motivate his colleagues. With a vision for innovation, he invented ERT's breakthrough and proprietary EXPERT® technology platform for centralized electronic electrocardiograph data collection and management. As the leader of ERT's world-renowned cardiology team, Dr. Morganroth provides comprehensive, strategic consultation on medical and regulatory cardiac safety issues. Having served as a consultant for the US FDA and regulatory authorities in Canada and Europe for many years, he has helped ERT to develop new solutions for assessing cardiac safety of new drugs in compliance with worldwide legislation with the ultimate aim of safeguarding human health.
Dr. Morganroth has contributed to the advancement of individuals and science in a number of different roles, from faculty, special government and consultant positions to memberships in major cardiology organizations. He has co-authored more than 350 articles and 24 books, he has been featured in different "Who's Who" listings, and has received a Special Citation award from the FDA Commissioner for his work in providing invaluable assistance to the FDA for the development of a format for regulatory submission of digital annotated electrocardiograms (ECGs) to determine the cardiac safety of new drugs.
Dr. Michael McKelvey, Chief Executive Officer of ERT, comments: "A globally recognized cardiologist and clinical researcher, Dr. Morganroth has been instrumental in defining the opportunity in cardiac safety that has shaped the direction of ERT beginning in the late 1970s. He has managed to successfully define an innovative set of processes and technologies that have helped lead ERT to its position as the clinical trial research industry's largest Cardiac Safety services company. Being named one of the 100 most inspiring people in the life sciences industry is in recognition of his exceptional career and a great honor for ERT as well."
For further information on ERT and its technology and services, please email email@example.com, call +1 215 972 0420 or visit www.ert.com.
For further press information, please contact Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477 539540, email firstname.lastname@example.org.
Based in Philadelphia, PA, eResearchTechnology, Inc. (www.ert.com) is a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries. The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. It is also a leading provider of centralized respiratory technology and services to evaluate pulmonary function efficacy and safety in clinical development. Sponsors can further use the Company's solutions to streamline the clinical trials process by automating the collection, analysis, and distribution of ePRO clinical data using multi-mode technology in all phases of clinical development as well as selected medical devices for the clinical trials and healthcare industries.
Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Subscribe to our Free Newsletters!